4017:TADAWULDr. Soliman Abdul Kader Fakeeh Hospital Co. Analysis

Dr. Soliman Abdel Kader Fakeeh Hospital is trading above its short‑term moving average but below its longer‑term averages, indicating a short‑term bullish tilt within a broader bearish backdrop. The RSI sits near the midpoint, suggesting neither overbought nor oversold conditions, while the MACD histogram has turned positive, offering a modest technical upside. Fundamentally, the company delivers steady revenue growth and modest profitability, yet the market price exceeds both the DCF‑derived fair value and the industry PE benchmark, pointing to an overvalued valuation. The dividend payout is modest with a low payout ratio, supporting sustainability, and the firm benefits from low beta but elevated recent volatility and a decreasing volume trend, which together raise liquidity concerns.
The recent inclusion of the Jeddah hospital in a global healthcare listing adds a positive brand narrative, but the overall risk profile remains mixed, with sector and regulatory considerations offset by geographic stability.